These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents.
    Author: Newton DL, Hansen HJ, Liu H, Ruby D, Iordanov MS, Magun BE, Goldenberg DM, Rybak SM.
    Journal: Crit Rev Oncol Hematol; 2001; 39(1-2):79-86. PubMed ID: 11418304.
    Abstract:
    Targeting CD22 on human B-cells with a monoclonal antibody conjugated to a cytotoxic RNAse causes potent and specific killing of the lymphoma cells in vitro. This translates to anti-tumor effects in human lymphoma models in SCID mice. RNA damage caused by RNAses could be an important alternative to standard DNA damaging chemotherapeutics. Moreover, targeted RNAses may overcome problems of toxicity and immunogenicity associated with plant or bacterial toxin containing immunotoxins.
    [Abstract] [Full Text] [Related] [New Search]